MedTrace Logo

An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne

NCT00725439 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2011-09-26

No results posted yet for this study

Summary

This study is looking at a new oral drug to treat acne. All patients in the study will get active drug, there is no placebo arm.

Conditions

Interventions

DRUG

Talarozole

Oral Dose 1.0 mg once daily

Sponsors & Collaborators

  • Stiefel, a GSK Company

    lead INDUSTRY

Principal Investigators

  • Prof. Dr. D. Roseeuw, MD · Department Dermatology, University Hospital Brussel (UZ Brussel)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2005-07-31
Completion
2007-12-31

Countries

  • Belgium
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00725439 on ClinicalTrials.gov